• Record revenue of $3.0 million, up 11% on previous quarter
• Remplir rollout in US market ahead of schedule, with first US surgeries completed
• Remplir study delivers compelling 81% success rate, no post-treatment complications

Orthocell Limited (ASX: OCC) has reported record revenue of $3.0 million for the September 2025 quarter, up 11% on the previous quarterly record of $2.7 million. This result represents the sixth consecutive quarter of record revenue, with a Compound Quarterly Growth Rate of 11% since Q2 FY24. The strong performance was primarily driven by growing sales of the company's flagship product, Remplir, in Australia and Singapore. The company also reported that the US rollout of Remplir is ahead of schedule, with a distributor network across 25 states covering 40% of the US population, first US surgeries completed, and over 100 surgeons now introduced to the product. Additionally, the company appointed its first distributor in the $75 million Canadian market, with first sales targeted for the December 2025 quarter. Orthocell also highlighted promising results from a Remplir study, which delivered a compelling 81% success rate with no post-treatment complications or adverse reactions reported. The company's leadership team was also strengthened with the appointment of a new Chief Financial Officer and Chief Commercial Officer, as well as a new Non-Executive Director.

Orthocell reported record quarterly revenue of $3.0 million, up 11% on the previous quarterly record of $2.7 million. The company expects revenue from Remplir sales in the US to build during the December 2025 quarter and grow into the second half of the financial year.

Orthocell is focused on continuing to grow sales in existing markets, expanding into the US and securing additional strategic international regulatory approvals for its Remplir product. The company is also accelerating the development of its tendon cell therapy in the US.